Use of bifunctional monoclonal antibodies for retargeting human lymphocytes against ovarian carcinoma cells
Over the past years intense efforts have been made to identify tumor specific or tumor associated markers which could be immunogenic in humans and animals. A considerable amount of data, which at least proves the existence of tumor associated antigens in humans, has been collected. Immunological techniques applied to diagnosis in oncology have allowed improvement, both in terms of sensitivity and specificity, in the area of pathology as well as in the laboratory and in nuclear medicine. More recently, the use of monoclonal antibodies (MAbs) derived by somatic hybridization  has allowed further improvement of results obtained with conventional antisera and opened new pathways in the field of research. In fact, these reagents possess a peculiar characteristic, that is, monospecificity, which makes them particularly suitable for immunological applications where the target of the immune response, the putative tumor antigen, is often undefined, possibly poorly immunogenic and difficult to identify.
KeywordsOvarian Carcinoma Human Ovarian Carcinoma Cell Human Ovarian Carcinoma Cell Line Ovarian Carcinoma Patient Bispecific Monoclonal Antibody
Unable to display preview. Download preview PDF.
- 6.Dillman, R.O. (1990) Human antimouse and antiglobulin responses to monoclonal antibodies. Immunoconj. Radiopharm., 3,1–15.Google Scholar
- 9.Rosenberg, S.A. (1992) The immunotherapy and gene therapy of cancer.J. Clin. Pathol, 10, 180–99.Google Scholar
- 19.Buraggi, G.L., Crippa, F., Landoni, L. et al. (1988) A new monoclonal antibody (MOvl8) against ovarian cancer for imaging and therapy. In Radioactive Isotopes in Clinical Medicine and Research, (eds. R. Hoffer and H. Bergman), Schattauer, Stuttgart, pp. 57–62.Google Scholar
- 21.Segal, D.M., Qian, J., Titus, J.A. et al. (1992) Targeted cytokine production. Int. J. Cancer, 52 (Suppl), 36–8.Google Scholar
- 22.Mezzanzanica, D., Neblock, D.S., Garrido, M.A. et al. (1990) In vivo retargeting of human T cells against human ovarian carcinoma by bifunctional F(ab’)2 antibodies. Antib. Immun. Radiopharm., 3, 81Google Scholar
- 24.Bolhuis, R.L.H., Lamers, C.H.J., Goey, H.S. et al. (1992) Adoptive immunotherapy of ovarian carcinoma with Bs-MAb targeted lymphocytes. A multicenter study. Int. J. Cancer, 7, 78–81.Google Scholar